Novo Nordisk A/S (NYSE:NVO) Shares Sold by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 26.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,452 shares of the company’s stock after selling 1,625 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $383,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Wendell David Associates Inc. increased its stake in Novo Nordisk A/S by 0.3% during the 4th quarter. Wendell David Associates Inc. now owns 76,847 shares of the company’s stock worth $6,610,000 after buying an additional 225 shares in the last quarter. Traynor Capital Management Inc. boosted its stake in shares of Novo Nordisk A/S by 4.8% in the fourth quarter. Traynor Capital Management Inc. now owns 320,162 shares of the company’s stock worth $27,540,000 after acquiring an additional 14,758 shares during the last quarter. Wesbanco Bank Inc. increased its position in shares of Novo Nordisk A/S by 22.9% during the fourth quarter. Wesbanco Bank Inc. now owns 103,116 shares of the company’s stock worth $8,870,000 after purchasing an additional 19,224 shares in the last quarter. SG Americas Securities LLC raised its stake in Novo Nordisk A/S by 379.8% in the 4th quarter. SG Americas Securities LLC now owns 107,725 shares of the company’s stock valued at $9,267,000 after purchasing an additional 85,272 shares during the last quarter. Finally, Phillips Wealth Planners LLC lifted its holdings in Novo Nordisk A/S by 8.0% in the 4th quarter. Phillips Wealth Planners LLC now owns 2,750 shares of the company’s stock valued at $237,000 after purchasing an additional 203 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on NVO shares. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Trading Down 0.5 %

NVO opened at $80.59 on Thursday. The stock has a market capitalization of $361.65 billion, a PE ratio of 26.08, a P/E/G ratio of 0.89 and a beta of 0.45. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The business’s 50 day moving average price is $96.10 and its 200 day moving average price is $115.79.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.